synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-25. Numbers and descriptions here follow the published literature rather than marketing material.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Chemotherapy, American Cancer Society Hazardous Drug Exposures in Health Care, National Institute for Occupational Safety and Health NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016, National Institute for Occupational Safety and Health International Ototoxicity Management Group (IOMG) - Wikiversity
==== Sequence-controlled radical polymerization ==== Radical polymerization is one of the most commonly used polymerization methods. About 50% of commercially available polymers are synthesized via radical polymerization. However, the disadvantages of this method are apparent that sequences and polymeric features cannot be well modulated. To overcome these constraints, scientists optimized the employed protocols. The first reported example was the time-controlled sequential addition of highly-reactive N-substituted maleimides in the atom transfer radical polymerization of styrene, which led to programmed sequences of functional monomers. The development of single-molecule addition into atom-transfer radical polymerization (ATRP), which enhances the sequence control of radical polymerization was also reported. Other solutions include the use of intermediate purification steps to isolate the desired oligomer sequence in between subsequent reversible addition−fragmentation chain-transfer polymerization (RAFT-polymerizations). Both flash column chromatography and recycling size exclusion chromatography have been proven successful in this regard. RAFT single unit monomer insertion (SUMI) is recently developed as an emerging technology for precise control of monomer sequence.
=== Pharmacodynamics === Suvomipic is listed as a dual mitochondrial pyruvate carrier (MPC) MPC1 and MPC2 inhibitor. It is thought to work by causing pyruvate accumulation, which in turn results in stimulation of lactate dehydrogenase (LDH) activity in hair follicle stem cells (HFSCs). As a result of this, lactic acid levels and glycolysis increase within the cells and more energy for cellular growth becomes available. It appears that changes in intracellular lactate availability may be a key mediator of the hair growth cycle, with low lactate levels resulting in dormancy or the telogen stage and high lactate levels resulting in active growth or the anagen stage. In the case of androgenic alopecia, hair follicles have miniaturized and permanently entered the telogen phase. According to its developers, suvomipic acts differently than existing hair loss drugs like minoxidil and finasteride in that it works via reactivating dormant hair follicles by altering HFSC metabolism. MPC inhibitors like UK-5099 (JXL001) and suvomipic have been found to stimulate hair growth in genetically modified mice in vivo and in excised human skin ex vivo. Another related approach to promoting hair growth is application of deoxyribose sugar gel, which was also effective in stimulating hair growth in mice.
Sources: en.wikipedia.org
Proteopedia Hemoglobin National Anemia Action Council at anemia.org New hemoglobin type causes mock diagnosis with pulse oxymeters Archived 2016-03-09 at the Wayback Machine at www.life-of-science.net Archived 2017-03-07 at the Wayback Machine Hemoglobin article at caloriebite.in
Jollibee offers American-influenced fast food items and casual Filipino fare. Among the establishment's best sellers are the Yumburger, the house hamburger first introduced during their early days of operation; the Chickenjoy, a fried chicken meal, introduced in the 1980s, with regular and spicy versions; and Jolly Spaghetti, a sweet Filipino spaghetti that includes a beef sauce with pieces of hot dog and ham. In 1995, Jollibee introduced the Burger Steak to its menu. At its international locations, Jollibee also offers localized products, such as chili chicken in Vietnam and nasi lemak in Brunei. Jollibee serves Coca-Cola products in Luzon and Visayas and Pepsi products in Mindanao and its overseas markets.
=== Linear traps and 3D trap === 3D ion trap (or Paul trap) mass spectrometers are widely used but have limitations. With a continuous source, such as one utilizing electrospray ionization (ESI), ions generated while the 3D trap is processing other ions are not used, thereby limiting the duty cycle. Furthermore, the total number of ions that can be stored in a 3D ion trap is limited by space charge effects. Combining a linear trap with a 3D trap can help overcome these limitations. Recently, Hardman and Makarov have described the use of a linear quadrupole trap to store ions formed by ESI for injection into an orbitrap mass analyzer. Ions passed through an orifice and skimmer, a quadrupole ion guide for ion cooling and then entered the quadrupole storage trap. The quadrupole trap has two rod sets; short rods near the exit were biased so that most ions accumulated in this region. Because the orbitrap requires that ions be injected in very short pulses, kilovolt ion extraction potentials were applied to the exit aperture. Flight times of ions to the orbitrap were mass dependent, but for a given mass, ions were injected in bunches less than 100 nanoseconds wide (fwhm).
ATP hydrolysis by AAA ATPases is proposed to involve nucleophilic attack on the ATP gamma-phosphate by an activated water molecule, leading to movement of the N-terminal and C-terminal AAA subdomains relative to each other. This movement allows the exertion of mechanical force, amplified by other ATPase domains within the same oligomeric structure. The additional domains in the protein allow for regulation or direction of the force towards different goals.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.